EPISODE · Jul 22, 2026 · 28 MIN
Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies
from Decera Clinical Education Oncology Podcast · host Paul E. Oberstein MD, Andrew H. Ko MD FASCO, Efrat Dotan MD MTR
In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including: The evolving role of chemotherapy Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease The potential impact of these developments on future treatment sequencing and supportive care Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Paul E. Oberstein, MD, MS Section Chief, GI Oncology Associate Professor of Medicine Co-Director, KRAS Excellence Initiative Perlmutter Cancer Center NYU Langone Health New York, New York Andrew H. Ko, MD, FASCO Professor of Medicine and Associate Chief Division of Hematology/Oncology University of California San Francisco San Francisco, California Efrat Dotan, MD, MTR Clinical Professor of Medicine (Hematology/Oncology) Executive Medical Director, Penn Medicine, Ann B. Barshinger Cancer Center Penn Center for Cancer Care Innovation, Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Link to full program: https://bit.ly/44HPR1U Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
With updates from the 2026 ASCO Annual Conference signaling long-awaited progress in pancreatic cancer, expert faculty review and discuss recent advances that may influence therapeutic decision-making in a historically chemotherapy-centered field. They examine the current role and limitations of multiagent chemotherapy, the growing importance of early germline and somatic testing, and emerging data for RAS-targeted therapies, including pan-RAS inhibition and allele-specific approaches. Faculty also discuss how molecular subsets such as KRAS wild-type disease, NRG1 fusions, CLDN18.2 expression, MTAP loss, and other actionable alterations may shape future treatment selection, sequencing, clinical trial enrollment, and supportive care planning for patients with pancreatic cancer.
NOW PLAYING
Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.